GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Equity-to-Asset

BOLD (Boundless Bio) Equity-to-Asset : 0.95 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Boundless Bio's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $179.25 Mil. Boundless Bio's Total Assets for the quarter that ended in Jun. 2024 was $188.20 Mil.

The historical rank and industry rank for Boundless Bio's Equity-to-Asset or its related term are showing as below:

BOLD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.21   Med: -0.81   Max: 0.95
Current: 0.95

During the past 3 years, the highest Equity to Asset Ratio of Boundless Bio was 0.95. The lowest was -1.21. And the median was -0.81.

BOLD's Equity-to-Asset is ranked better than
94.39% of 1516 companies
in the Biotechnology industry
Industry Median: 0.67 vs BOLD: 0.95

Boundless Bio Equity-to-Asset Historical Data

The historical data trend for Boundless Bio's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Equity-to-Asset Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Equity-to-Asset
-0.34 -1.06 -0.98

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.67 -0.81 -0.98 -1.21 0.95

Competitive Comparison of Boundless Bio's Equity-to-Asset

For the Biotechnology subindustry, Boundless Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Equity-to-Asset falls into.


Boundless Bio Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Boundless Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-127.082/129.894
=

Boundless Bio's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

Equity to Asset (Q: Jun. 2024 )=Total Stockholders Equity/Total Assets
=179.246/188.203
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boundless Bio  (NAS:BOLD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Boundless Bio Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Equity-to-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Website
https://www.boundlessbio.com
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.